Effect Of Rilapladib (SB-659032) On Platelet Aggregation

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Healthy Subjects; Atherosclerosis

Treatments: Drug: Rilapladib (SB-659032)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00387257

LP2108364

Details and patient eligibility

About

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Enrollment: 58 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects with QTc < 450 msec as measured at screening.

Exclusion criteria

• History of asthma.
• Smokers.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind